Korean J Intern Med.  2022 May;37(3):520-533. 10.3904/kjim.2021.518.

Omics-based biomarkers for diagnosis and prediction of kidney allograft rejection

• Lim JH
• Chung BH
• Lee SH
• Jung HY
• Choi JY
• Cho JH
• Park SH
• Kim YL
• Kim CD

• KMID: 2529650
• DOI: http://doi.org/10.3904/kjim.2021.518

Abstract

Kidney transplantation is the preferred treatment for patients with end-stage kidney disease, because it prolongs survival and improves quality of life. Allograft biopsy is the gold standard for diagnosing allograft rejection. However, it is invasive and reactive, and continuous monitoring is unrealistic. Various biomarkers for diagnosing allograft rejection have been developed over the last two decades based on omics technologies to overcome these limitations. Omics technologies are based on a holistic view of the molecules that constitute an individual. They include genomics, transcriptomics, proteomics, and metabolomics. The omics approach has dramatically accelerated biomarker discovery and enhanced our understanding of multifactorial biological processes in the field of transplantation. However, clinical application of omics-based biomarkers is limited by several issues. First, no large-scale prospective randomized controlled trial has been conducted to compare omics-based biomarkers with traditional biomarkers for rejection. Second, given the variety and complexity of injuries that a kidney allograft may experience, it is likely that no single omics approach will suffice to predict rejection or outcome. Therefore, integrated methods using multiomics technologies are needed. Herein, we introduce omics technologies and review the latest literature on omics biomarkers predictive of allograft rejection in kidney transplant recipients.

Keyword

Omics; Biomarkers; Graft rejection; Kidney transplantation